eccogene glp 1 Non‐clinical and first‐in‐human characterization of ECC5004/AZD5004, a novel once‐daily, oral small‐molecule GLP‐1 receptor agonist - Haggag - 2025 - Diabetes, Obesity and Metabolism AstraZeneca licenses Eccogene's oral GLP-1
Description
Theres a reason they are all gastrointestinal: GLP-1s impact gut hormones and slow down gastric emptying (or how quickly you digest food), which can trigger the side effects
His story blends personal honesty with advocacy, showing patients that success is possible but requires commitment, access, and professional support
In a study that will be published soon, Dr
Beyond that, some other potential risks included sleep issues, low blood pressure (sometimes leading to fainting), kidney stones, arthritis, and acute pancreatitis
